Skip to main content
OpenTrials
Completed

NCT Number: NCT01789658

Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation

Oral mucositis (OM) is a common adverse effect of chemotherapy, radiotherapy and conditioning regimens before Hematopoietic Stem Cell Transplantation (HSCT). The aim of this study is to effectiveness of cryotherapy as a prophylactic treatment in children undergoing HSCT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pediatric Oncology Department, Queen Silvia Childrens´ Hospital, Gothenburg, Sweden

Loading trial locations.

About this study

There is a complex pathobiology behind OM; chemo and radiotherapy affects the mucosa and submucosa causing DNA-strand brakes and generation of reactive oxygen species (ROS). This initiates a cascade of events, among others activation of transcription factors, up-regulation of pro-inflammatory cytokines, and activation of macrophages and proteases leading to tissue injury causing symptoms such as erythema, edema, ulceration, taste perception alterations, and mouth dryness. OM often causes local and systemic infections, fatigue, pain, and difficulties in basal functions such as swallowing (and hence drinking and eating) and talking and reduces patients' psychological well-being. Nearly 90 % of pediatric patients undergoing HSCT are afflicted with OM. In pediatric patients mucositis is reported as one of the most painful and debilitating side effects during cancer treatment.Beyond a significant suffering for the patient it is hence associated with higher costs for health care and increased mortality.

The current scientific situation regarding prevention and treatment of OM has been summarized in Cochrane reports showing limited data on adults and practically missing data on children and adolescents. Concluding guidelines from these reports emphasize the need for well conducted randomized controlled trials (RCT's) to evaluate and refine treatments in order to establish evidence based interventions.

The use of cryotherapy to prevent oral mucositis in patients who are receiving high-dose chemotherapy as a conditioning agent prior to HSCT continue to show evidence in the adult population.

The aim of this study is to compare treatment with cryotherapy (Arm 1)with a standard oral care protocal (Arm 2)

ARM 1 Children are instructed to use chew on ice-chips, ingest ice-cream or ice-water during infusion of chemotherapy as part of the conditioning treatment prior to HSCT. Melted ice should be replaced by new as soon as possible. Children receiving a 24-hour infusion are instructed to use cryotherapy for one hour 4 times a day.

ARM 2 Standard care for prevention and management of oral mucositis

Primary outcome

  • Degree and duration of Oral mucositis

Secondary outcomes

  • Oral pain
  • Opioid use
  • Duration of parenteral nutrition
  • Weight loss
  • Duration of neutropenic fever
  • Duration of antibiotic treatment
  • Duration of hospitalization
  • Emotional and psychological status
  • C reactive protein (CRP) and s-albumin correlation to grade of Oral Mucositis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age between 4-18 Undergoing Hematopoietic Stem Cell Transplantation in Sweden sufficient knowledge in swedish to understand the protocols -

Exclusion criteria

-

Treatment and study plan

Cryotherapy

Other

Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.

Primary outcomes

  1. Mucositis grade - WHO Oral Toxicity Scale

    Time frame: Daily until engraftment, an expected average of 20 days.

    WHO-Oral toxicity scale Grade 0 - No mucositis Grade 1 - Erythema and/or soreness Grade 2 - Erythema and/or ulcers. Can eat solid food. Grade 3 - Erythema and/or Ulcers. No solid food but can ingest liquids. Grade 4 - Oral alimentation not possible.

Secondary outcomes

  1. Mucositis grade - Children´s International Mucositis Evaluation Scale (ChiMES)

    Time frame: Daily until engraftment, an expected average of 20 days.

    Daily evaluation by child and parent.

  2. Pain - Childrens Hospital Eastern Ontario Pain Scale (CHEOPS)

    Time frame: Daily until Engraftment an expected average of 20 days.

    Daily assessment by nurse

  3. Mouth Pain

    Time frame: Daily until Engraftment an expected average of 20 days

    Mouth Pain measured with Numerical Rating scale(NRS)for children >7 years and parents and Facial Pain Scale(FPS) for children < 7 years

  4. Emotional and Psychological status

    Time frame: Daily until engraftment, an expected average of 20 days.

    Beck youth inventories for depression and anxiety

Other outcomes

  1. Opioid consumption

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Days with, and dose of morphine-equivalent opioids

  2. Duration of parenteral nutrition

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Days with Total Parenteral Nutrition

  3. Weight Loss

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Weight Loss in kilograms from admission to date of engraftment

  4. Duration of Antibiotic treatment

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Days with antibiotics

  5. Duration of febrile neutropenia

    Time frame: Until engraftment, an expected average of 20 days

    Days with fever >38.0 degrees

  6. Duration of Hospitalisation

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Counted from day 0 until discharge either home or to region hospital.

  7. C reactive protein

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    Level of p-CRP in comparison to grade of mucositis

  8. S-Albumin

    Time frame: During hospitalization in connection with HSCT, an expected average of 25 days

    In correlation to grade of Oral Mucositis

Sponsors and collaborators

Lead sponsor

Uppsala University

Other

Collaborators

  • The Swedish Childhood Cancer Foundation

Registry information

Official study title

A Randomized Controlled Trial of Cryotherapy for Prevention and Reduction of Severity of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Feb 12, 2013
Registry last updated
Oct 27, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.